HER2-positive Breast Cancer Clinical Trials

23 studies are recruiting for her2-positive breast cancer in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

   The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   University of San Diego Moores Cancer Center, La Jolla, California

   Locations

   77 in total

   Run by

   PMV Pharmaceuticals, Inc

   See if you can join NCT04585750 on ClinicalTrials.gov

2. Study of Screening Brain MRIs in Stage IV Breast Cancer

   The study is a single arm, nonrandomized phase II prospective study, with the goal of investigating the role of screening brain MRIs in neurologically asymptomatic patients with metastatic breast cancer.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Morton Plant Mease- Baycare, Clearwater, Florida

   Locations

   2 in total

   Run by

   H. Lee Moffitt Cancer Center and Research Institute

   See if you can join NCT05115474 on ClinicalTrials.gov

3. Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases

   The purpose of this study is to determine whether AGuIX (Activation and Guidance of Irradiation by X-ray) gadolinium-based nanoparticles make radiation work more effectively in the treatment of patients with brain metastases that are more difficult to control with stereotactic radiation alone.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Brigham and Women's Hospital, Boston, Massachusetts

   Locations

   2 in total

   Run by

   Brigham and Women's Hospital

   See if you can join NCT04899908 on ClinicalTrials.gov

4. A Phase 1/1b Study of IAM1363 in HER2 Cancers

   This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCSD Moores Cancer Center, La Jolla, California

   Locations

   53 in total

   Run by

   Iambic Therapeutics, Inc

   See if you can join NCT06253871 on ClinicalTrials.gov

5. Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

   Patient will be treated with neratinib, an aromatase inhibitor and trastuzumab for 24 weeks prior to surgery, following an initial 3 weeks of neratinib alone, aromatase inhibitor alone or the combination of neratinib and an aromatase inhibitor. A breast biopsy will be performed prior to Day 1 of we…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Illinois Cancer Center, Chicago, Illinois

   Locations

   4 in total

   Run by

   Ruth O'Regan

   See if you can join NCT04886531 on ClinicalTrials.gov

6. RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

   The purpose of this study is to assess the efficacy and safety of RO7771950 in combination with trastuzumab and capecitabine, compared to tucatinib in combination with trastuzumab and capecitabine.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Astera Cancer Care East Brunswick, East Brunswick, New Jersey

   Locations

   186 in total

   Run by

   Hoffmann-La Roche

   See if you can join NCT07413939 on ClinicalTrials.gov

7. PRE-ISPY Phase I/II Oncology Platform Program

   PRE-ISPY Phase I/II (I-SPY-P1) is an open-label, multisite platform study with multiple ongoing drug regimen arms added by protocol amendment which is designed to evaluate single agents or combinations in locally advanced, incurable, or metastatic solid tumors and/or oligometastatic malignancy and/…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham, Alabama

   Locations

   10 in total

   Run by

   QuantumLeap Healthcare Collaborative

   See if you can join NCT05868226 on ClinicalTrials.gov

8. HER-2 B Cell Peptide Vaccine

   This phase I trial studies the side effects and best dose of vaccine therapy in treating patients with metastatic solid tumors. Vaccines made from antibodies and peptides combined with tumor cells may help the body build an effective immune response to kill tumor cells.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Indiana University Melvin & Bren Simon Comprehensive Cancer Center, Indianpolis, Indiana

   Run by

   Pravin T.P Kaumaya

   See if you can join NCT06414733 on ClinicalTrials.gov

9. HER2 Vaccine for Locally Advanced Breast Cancer

   The goal of this study is to test an investigational vaccine to activate the immune system to fight breast cancer.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Indiana University Melvin & Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana

   Run by

   Pravin T.P Kaumaya

   See if you can join NCT06949410 on ClinicalTrials.gov

10. Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast Cancer

    The purpose of this study is to test whether four different supportive care programs can reduce fatigue in women with advanced or metastatic breast cancer who are receiving a medication called a CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) alongwith endocrine therapy with or without a…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Miami, Miami, Florida

    Locations

    3 in total

    Run by

    University of Miami

    See if you can join NCT06123988 on ClinicalTrials.gov

11. A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

    The purpose of this study is to see if zanidatamab is safe and effective, when combined with chemotherapy, in treating people who has Human Epidermal Growth Factor Receptor 2 (HER2)-positive, early-stage breast cancer

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Oncology Institute, Long Beach, California

    Locations

    35 in total

    Run by

    Jazz Pharmaceuticals

    See if you can join NCT07102381 on ClinicalTrials.gov

12. BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer

    Adult men and women with early-stage, IHC/FISH-defined HER2-positive breast cancer will have a MammaPrint®/BluePrint® assay performed on the diagnostic biopsy specimen, ordered by the treating Oncologist as standard care

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of Illinois, Chicago, Illinois

    Run by

    University of Illinois at Chicago

    See if you can join NCT06441890 on ClinicalTrials.gov

13. HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission

    Thie purpose of this study is to find out whether a personalized treatment approach-using a series of ctDNA tests along with standard imaging scans to help decide when to step up (escalate) or decrease (de-escalate) sequential treatments (given one after another)-combined with local therapies (whic…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

    Locations

    7 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT07459673 on ClinicalTrials.gov

14. ATEMPT 2.0: Adjuvant T-DM1 vs TH

    This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery. The name of the study drugs involved are: * Trastuzumab-emtansine (T-DM1…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California

    Locations

    53 in total

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT04893109 on ClinicalTrials.gov

15. Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI

    The purpose of the study is to see if using an investigational drug called [18F]FMISO with PET/MRI imaging can help monitor and predict the effect of trastuzumab (Herceptin) on chemotherapy in patients diagnosed with advanced HER2 positive breast cancer. This study is for imaging purposes only and …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Alabama at Birmingham, Birmingham, Alabama

    Run by

    University of Alabama at Birmingham

    See if you can join NCT04332588 on ClinicalTrials.gov

16. The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

    The purpose of this study is to test the safety and effectiveness of a sequence of drugs (a Taxane plus Trastuzumab plus Pertuzumab followed by Trastuzumab Deruxtecan, followed by Tucatinib plus Ado-Trastuzumab Emtansine (T-DM1), followed by Trastuzumab plus Pertuzumab plus Tucatinib) in HER2+ Brea…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Dana-Farber Cancer Institute, Boston, Massachusetts

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT06439693 on ClinicalTrials.gov

17. A Study of Surgery and Radiotherapy in People With Breast Cancer

    The researchers are doing this study to see if the combination of surgery, locoregional radiation therapy, SBRT (stereotactic body radiation therapy), and the usual approach is more effective in treating oligometastatic HER2-positive breast cancer than the usual approach alone. The researchers will…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

    Locations

    7 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT07053085 on ClinicalTrials.gov

18. I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

    The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators of response (tumor analysis prior to surgery via magnetic res…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of Alabama at Birmingham, Birmingham, Alabama

    Locations

    42 in total

    Run by

    QuantumLeap Healthcare Collaborative

    See if you can join NCT01042379 on ClinicalTrials.gov

19. Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab

    The purpose of the study is to find out if an investigational drug called Dendritic Cell (DC1) vaccine added to standard neoadjuvant (given before main treatment) therapy can help people with HER2 (human epidermal growth factor receptor 2) positive breast cancer.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Moffitt Cancer Center, Tampa, Florida

    Run by

    H. Lee Moffitt Cancer Center and Research Institute

    See if you can join NCT05325632 on ClinicalTrials.gov

20. NearWave Optical Molecular Monitoring

    The purpose of this study is to assess the feasibility of the NearWave optical molecular monitoring system for monitoring therapy progression and predicting pathologic complete response (pCR) of breast cancer patients undergoing neoadjuvant chemotherapy (NAC).

    Stage

    Not phased

    Ages

    18 and older

    Site

    Indiana University Simon Comprehensive Cancer Center, Indianapolis, Indiana

    Run by

    Indiana University

    See if you can join NCT06744465 on ClinicalTrials.gov

21. Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer

    The purpose of this study is to compare a special type of mammogram that uses a contrast agent called contrast-enhanced digital mammography with contrast-enhanced digital breast tomosynthesis (CEDM+CEDBT), with breast magnetic resonance imaging imaging (MRI) for predicting the effect of neoadjuvant…

    Stage

    EARLY_Phase 1

    Ages

    18 and older

    Site

    Stony Brook Breast Center, Stony Brook, New York

    Run by

    Alison Stopeck

    See if you can join NCT06220214 on ClinicalTrials.gov

22. TRUDI: TDXD+Durva in HER2+/Low IBC

    The purpose of this study is to test the safety and effectiveness of an investigational drug combination (trastuzumab deruxtecan and durvalumab) to learn whether the intervention works in treating Human Epidermal growth factor Receptor-2 (HER2)-expressing inflammatory breast cancer. The names of th…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Brigham and Women's Hospital, Boston, Massachusetts

    Locations

    3 in total

    Run by

    Filipa Lynce, MD

    See if you can join NCT05795101 on ClinicalTrials.gov

23. Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer

    The purpose of this study is to learn whether clinical response (the amount a tumor shrinks based on imaging or tumor measurements obtained by physical exam) predicts pathologic response (the amount of tumor remaining when surgery is performed) in participants with breast cancer who are receiving c…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Harris Health System - Smith Clinic, Houston, Texas

    Locations

    2 in total

    Run by

    Baylor Breast Care Center

    See if you can join NCT05020860 on ClinicalTrials.gov